PROCEPT BioRobotics Corporation, a surgical robotics company focused on improving patient care with advanced urology solutions, announced a significant regulatory milestone. Aquablation therapy, a treatment for benign prostatic hyperplasia $(BPH.AU)$, has been assigned a Category I Current Procedural Terminology $(CPT)$ code effective January 1, 2026. This new designation, replacing the previous Category III code, underscores the clinical value and widespread adoption of Aquablation therapy. It is expected to enhance surgeon adoption and broaden patient access, offering a treatment option that provides durable symptom relief with minimal risk of sexual side effects. The 2026 Medicare Proposed Physician Fee Schedule includes this new Category I code, proposing a national average payment of approximately $540, slightly higher than the traditional TURP procedure. The final rule is anticipated in November 2025, with implementation set for January 1, 2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。